Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III studyVito Lorusso, Giuseppe Colucci, Francesco Giotta et al.|International Journal of Oncology|2014Cited by 26
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, PierFranco Conte, Sara Balduzzi et al.|BMC Medicine|2019Cited by 25
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experienceMariangela Ciccarese, Giammarco Surico, Maria Morritti et al.|Breast Cancer Research and Treatment|2017Cited by 12
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic SettingDaniele Generali, Gabriella Mariani, Filippo Montemurro et al.|The Oncologist|2017Cited by 11
Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology GroupGiuseppe Colucci, Francesco Giotta, Vittorio Gebbia et al.|Anti-Cancer Drugs|1997Cited by 3